• <xmp id="kkgi4">
    <td id="kkgi4"><kbd id="kkgi4"></kbd></td>
  • <td id="kkgi4"></td>
  • <table id="kkgi4"><noscript id="kkgi4"></noscript></table>
  • 愛硒健康網丨癌癥腫瘤治療助手

    2023 ASCO中國之聲 | 頭頸部腫瘤壁報部分中國研究匯總!

    一年一度的全球腫瘤界盛會-美國臨床腫瘤學會(ASCO)年會將于當地時間6月2日-6月6日召開。ASCO年會是世界上規模最大、學術水平最高、最具權威的臨床腫瘤學會議,致力于癌癥的預防、治療和改善患者管理,以展示腫瘤的基礎研究和臨床最新研究為特點,討論當前國際先進的治療方法。

    隨著中國臨床研究在腫瘤領域的快速成長,中國在世界腫瘤領域中也發揮著日益重要的作用。此次會議上,頭頸部腫瘤領域Poster Session中國共入選20項研究。期待中國專家在ASCO年會上展現風采!

    頭頸部腫瘤

    Head and Neck Cancer

    摘要號: 6024

    標題:Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.

    報告人: 孔芳芳

    單位:復旦大學附屬腫瘤醫院

    摘要號: 6026

    標題:A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

    報告人:麥海強

    單位:中山大學腫瘤防治中心

    摘要號: 6030

    標題:Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.

    報告人:陳曦

    單位:中山大學腫瘤防治中心

    摘要號: 6031

    標題:Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.

    報告人:Nian Lu

    單位:中山大學腫瘤防治中心

    摘要號: 6037

    標題:Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).

    報告人:薛麗瓊

    單位:同濟大學附屬東方醫院

    摘要號: 6047

    標題:TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

    報告人:Ling Peng

    單位:廣東天科雅生物醫藥科技有限公司

    摘要號: 6049

    標題:Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.

    報告人:馮梅

    單位:四川省腫瘤醫院

    摘要號: 6064

    標題:Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.

    報告人:孔芳芳

    單位:復旦大學附屬腫瘤醫院

    摘要號: 6067

    標題:Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial.

    報告人:Chen Fangzheng

    單位:廣州醫科大學附屬腫瘤醫院

    摘要號: 6068

    標題:Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.

    報告人:區曉敏

    單位:復旦大學附屬腫瘤醫院

    摘要號: 6069

    標題:A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.

    報告人:Di Wu

    單位:中山大學腫瘤防治中心

    摘要號: 6070

    標題:Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.

    報告人:白春梅

    單位:北京協和醫院

    摘要號: 6071

    標題:Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial.

    報告人:呂星

    單位:中山大學腫瘤防治中心

    摘要號: 6072

    標題:Prospective study of integrating post-radiotherapy [18F] fluorodeoxyglucose-positron emission tomography/computed tomography scan and plasma Epstein-Barr virus DNA in surveillance of locoregionally advanced nasopharyngeal carcinoma.

    報告人:唐林泉

    單位:中山大學腫瘤防治中心

    摘要號: 6077

    標題:Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.

    報告人:陳艷峰

    單位:中山大學腫瘤防治中心

    摘要號: 6078

    標題:Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.

    報告人:劉志剛

    單位:南方醫科大學附屬東莞醫院腫瘤中心

    摘要號: 6080

    標題:Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.

    報告人:閆婧

    單位:南京大學醫學院附屬鼓樓醫院

    摘要號: 6087

    標題:Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.

    報告人:桂琳

    單位:中國醫學科學院附屬腫瘤醫院

    摘要號: 6089

    標題:A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

    報告人:季冬梅

    單位:復旦大學附屬腫瘤醫院

    摘要號: TPS6112

    標題:Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.

    報告人:胡超蘇

    單位:復旦大學附屬腫瘤醫院

    備注:排名不分先后,按照摘要號進

    加硒教授微信:623296388,送食療電子書,任選一本

    分享到:更多 ()

    評論 搶沙發

    • 昵稱 (必填)
    • 郵箱 (必填)
    • 網址
  • <xmp id="kkgi4">
    <td id="kkgi4"><kbd id="kkgi4"></kbd></td>
  • <td id="kkgi4"></td>
  • <table id="kkgi4"><noscript id="kkgi4"></noscript></table>
  • 国产又粗又猛又爽又黄的视频